Original language | English (US) |
---|---|
Pages (from-to) | 3-5 |
Number of pages | 3 |
Journal | Cancer Cell |
Volume | 40 |
Issue number | 1 |
DOIs | |
State | Published - Jan 10 2022 |
ASJC Scopus subject areas
- Oncology
- Cell Biology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Cancer Cell, Vol. 40, No. 1, 10.01.2022, p. 3-5.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer
AU - Shapiro, Lauren C.
AU - Thakkar, Astha
AU - Campbell, Sean T.
AU - Forest, Stefanie K.
AU - Pradhan, Kith
AU - Gonzalez-Lugo, Jesus D.
AU - Quinn, Ryann
AU - Bhagat, Tushar D.
AU - Choudhary, Gaurav S.
AU - McCort, Margaret
AU - Sica, R. Alejandro
AU - Goldfinger, Mendel
AU - Goel, Swati
AU - Anampa, Jesus D.
AU - Levitz, David
AU - Fromowitz, Ariel
AU - Shah, Akash Pradip
AU - Sklow, Charlotte
AU - Alfieri, Gregory
AU - Racine, Andrew
AU - Wolgast, Lucia
AU - Greenberger, Lee
AU - Verma, Amit
AU - Halmos, Balazs
N1 - Funding Information: The authors would like to acknowledge the help of Tanya Riedl and the Montefiore Vaccine Center. The authors acknowledge LLS Award IRV-BC0004-22 , Cancer Center grant P30 CA013330 , and NCORP grant 2UG1CA189859-06 in providing funding for this project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding Information: The authors would like to acknowledge the help of Tanya Riedl and the Montefiore Vaccine Center. The authors acknowledge LLS Award IRV-BC0004-22, Cancer Center grant P30 CA013330, and NCORP grant 2UG1CA189859-06 in providing funding for this project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. L.C.S. A.T. A.V. and B.H. conceived and managed the study; J.D.G.-L. R.Q. M.M. R.A.S. M.G. S.G. J.D.A.M. D.L. A.F. A.P.S. C.S. G.A. and L.G. participated in patient recruitment; L.C.S. A.T. J.D.G.-L. R.Q. C.S. and G.A participated in data curation; T.D.B. and G.S.C. participated in laboratory investigations; K.P. oversaw data analyses; A.R. contributed to project administration; S.C. S.F. and L.W. oversaw investigations. All authors contributed to writing the manuscript. R.A.S. serves as a consultant with Morphosys and Miragen and is on the faculty at Physicians? Education Research. A.V. has received research funding from GlaxoSmithKline, BMS, Janssen, Incyte, MedPacto, Celgene, Novartis, Curis, Prelude, and Eli Lilly and Company; has received compensation as a scientific advisor to Novartis, Stelexis Therapeutics, Acceleron Pharma, and Celgene; and has equity ownership in Stelexis Therapeutics. All other authors declare no competing interests.
PY - 2022/1/10
Y1 - 2022/1/10
UR - http://www.scopus.com/inward/record.url?scp=85122311625&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122311625&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2021.11.006
DO - 10.1016/j.ccell.2021.11.006
M3 - Letter
C2 - 34838186
AN - SCOPUS:85122311625
SN - 1535-6108
VL - 40
SP - 3
EP - 5
JO - Cancer Cell
JF - Cancer Cell
IS - 1
ER -